A population approach to disease management: Hepatitis C direct-acting antiviral use in a large health care system

Journal of Managed Care Pharmacy

Volumn 20, Issue 6, 2014, Pages 533-540

  Belperio, Pamela S ^c   Backus, Lisa I ^a   Ross, David ^b   Neuhauser, Melinda M ^b   Mole, Larry A ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BOCEPREVIR; GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; BIOLOGICAL MARKER; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; VIRUS RNA; HEMOGLOBIN;

ADJUVANT THERAPY; ADVERSE OUTCOME; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; DISEASE SURVEILLANCE; DRUG COST; HEALTH CARE SYSTEM; HEPATITIS C; HUMAN; PHARMACIST; PRESCRIPTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VETERAN; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; EDUCATION; GENETICS; GOVERNMENT; HEALTH CARE DELIVERY; HEPACIVIRUS; MEDICAL EDUCATION; MEDICATION THERAPY MANAGEMENT; PHARMACY; PRACTICE GUIDELINE; REGISTER; TIME; UNITED STATES; VIRUS LOAD; ALCOHOL CONSUMPTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; CONGESTIVE HEART FAILURE; DEPRESSION; DRUG APPROVAL; DRUG UPTAKE; DRUG USE; HEALTH EDUCATION; HEPATITIS C VIRUS GENOTYPE 1; MEDICATION COMPLIANCE; NEUTROPHIL COUNT; SCHIZOPHRENIA;

ANEMIA; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; COMPARATIVE EFFECTIVENESS RESEARCH; DELIVERY OF HEALTH CARE; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; EDUCATION, MEDICAL, CONTINUING; EDUCATION, PHARMACY, CONTINUING; GUIDELINE ADHERENCE; HEMATINICS; HEPACIVIRUS; HEPATITIS C; HUMANS; MEDICATION THERAPY MANAGEMENT; OLIGOPEPTIDES; PHARMACEUTICAL SERVICES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROLINE; REGISTRIES; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VIRAL LOAD;

EID: 84901242205     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.6.533     Document Type: Article

References (17)

1. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36(5 Suppl 1):S30-S34.
2. U.S. Department of Veterans Affairs. State of care for veterans with chronic hepatitis C. November 2010. Available at: http://www.hepatitis.va.gov/ provider/policy/HCV-state-of-care-2010.asp. Accessed August 29, 2012.
3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-14.
4. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-16.
6. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17.
7. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-28.
8. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-44.
9. Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis. 2012;12(9):717-28.
10. Tungol A, Rademacher K, Schafer JA. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. J Manag Care Pharm. 2011;17(9):685-94. Available at: http://www.amcp.org/ WorkArea/DownloadAsset.aspx?id=13668.
11. Backus LI, Gavrilov S, Loomis TP, et al. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc. 2009;16(6):775-83.
12. Victrelis (boceprevir) capsules for oral use. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Revised February 2014. Available at: http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_ pi.pdf. Accessed March 24, 2014.
13. Incivek (telaprevir) tablets for oral use. Vertex Pharmaceuticals, Inc. Revised October 2013. Available at: http://pi.vrtx.com/files/uspi_telaprevir.pdf. Accessed March 24, 2014.
14. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.
15. Belperio PS, Hwang EW, Thomas IC, Mole LA, Cheung R, Backus LI. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C. Clin Gastroenterol Hepatol. 2013;11(8):1021-27.
16. Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther. 2014;39(1):93-103.
17. Stryer DB, Siegel JE, Rodgers AB. Outcomes research: priorities for an evolving field. Med Care. 2004;42(4 Suppl):III1-5.